1-6 of 6
Christina Tekle
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status in Anti-CD38-Naïve Population

Xavier Leleu, Jean Fontan, Aurore Perrot, Lionel Karlin, Cyrille Touzeau, Samantha Schulmann, Salomon Manier, Karim Belhadj Merzoug, Adrien Trebouet, Patricia Zunic, Jean Marc Schiano De Colella, Christina Tekle, Marianne Gaucher, Olivier Decaux
Journal: Blood
Blood (2023) 142 (Supplement 1): 7419.
https://doi.org/10.1182/blood-2023-179532
Published: 2023
Journal Articles

The Impact of Isatuximab Regimens on Hypogammaglobulinemia Occurrence, Recovery, and Associated Infections in Patients with Relapsed/Refractory Multiple Myeloma

Cesar Rodriguez, Aurore Perrot, Paul G. Richardson, Thierry Facon, Ivan Spicka, Albert Oriol, Kenshi Suzuki, Edvan Crusoe, Ajai Chari, Nicole Armstrong, Christina Tekle, Marie-Laure Risse, Thomas Martin, Philippe Moreau
Journal: Blood
Blood (2023) 142 (Supplement 1): 1980.
https://doi.org/10.1182/blood-2023-179925
Published: 2023
Journal Articles

Updated Results from a Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Isatuximab Plus Pomalidomide and Dexamethasone Versus Daratumumab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma

Xavier Leleu, Thomas Delea, Patricia Guyot, Aaron Moynahan, Erin Singh, Christina Tekle, Peggy L Lin
Journal: Blood
Blood (2023) 142 (Supplement 1): 6732.
https://doi.org/10.1182/blood-2023-188703
Published: 2023
Journal Articles

Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment

Marcelo Capra, Thomas Martin, Philippe Moreau, Gracia Martinez, Albert Oriol, Youngil Koh, Hang Quach, Kwee Yong, Andreea Rawlings, Christina Tekle, Sandrine Macé, Marie-Laure Risse, Ivan Spicka
Journal: Blood
Blood (2022) 140 (Supplement 1): 7138–7140.
https://doi.org/10.1182/blood-2022-162731
Published: 2022
Journal Articles

Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status

Olivier Decaux, Radhia Lafore, Daniel Iaquinta, Christina Tekle, Xavier Leleu
Journal: Blood
Blood (2022) 140 (Supplement 1): 10969–10970.
https://doi.org/10.1182/blood-2022-162602
Published: 2022
Journal Articles

Isatuximab Plus Carfilzomib and Dexamethasone in Patients with Early Versus Late Relapsed Multiple Myeloma: Ikema Subgroup Analysis

Thierry Facon, Philippe Moreau, Ross Baker, Ludek Pour, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Lionel Karlin, Andreea Rawlings, Christina Tekle, Sandrine Schwab, Marie-Laure Risse, Thomas Martin
Journal: Blood
Blood (2022) 140 (Supplement 1): 1820–1822.
https://doi.org/10.1182/blood-2022-159105
Published: 2022